SYRE (Spyre Therapeutics) Interest Coverage : No Debt ⁽¹⁾ (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Spyre Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Spyre Therapeutics's Operating Income for the three months ended in Dec. 2024 was $-61.25 Mil. Spyre Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $0.00 Mil. Spyre Therapeutics has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Spyre Therapeutics Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Spyre Therapeutics's Interest Coverage or its related term are showing as below:

SYRE' s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

SYRE's Interest Coverage is ranked better than
98.92% of 369 companies
in the Biotechnology industry
Industry Median: 113.1 vs SYRE: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Spyre Therapeutics Interest Coverage Historical Data

The historical data trend for Spyre Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Spyre Therapeutics Interest Coverage Chart

Spyre Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Coverage

Get a 7-Day Free Trial

N/A

No Debt

Spyre Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Coverage	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Spyre Therapeutics's Interest Coverage

For the Biotechnology subindustry, Spyre Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spyre Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Interest Coverage falls into.

Save Embed

;

Save Embed

;

Spyre Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Spyre Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Spyre Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-208.57 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Spyre Therapeutics had no debt ⁽¹⁾.

Spyre Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the three months ended in Dec. 2024, Spyre Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-61.25 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Spyre Therapeutics had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

Spyre Therapeutics (NAS:SYRE) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Spyre Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Spyre Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Spyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spyre Therapeutics Inc (NAS:SYRE) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453

Website

https://www.spyre.com

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Executives

Scott L Burrows	officer: Chief Financial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Heidy King-jones	officer: See Remarks	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Fairmount Healthcare Co-invest L.p.	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Peter Evan Harwin	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Cameron Turtle	officer: Chief Operating Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Michael Thomas Henderson	director	421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p.	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p.	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jeff Marc Goldberg	director, officer: President and CEO	C/O AKCEA THERAPEUTICS, 55 CAMBRIDGE PARKWAY, STE 100, CAMBRIDGE MA 02142
Linda L Neuman	officer: Chief Medical Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Marcio Souza	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
James Paul Kastenmayer	officer: Interim CEO & General Counsel	ONE MEDIMMUNE WAY, FLOOR ONE, AREA TWO, GAITHERSBURG MD 20879
Hanley Jr. Michael Conick	officer: Chief Commercial Officer	C/O AEGLEA THERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746